BR112014016805A2 - compostos terapeuticamente ativos e seus métodos de uso - Google Patents

compostos terapeuticamente ativos e seus métodos de uso

Info

Publication number
BR112014016805A2
BR112014016805A2 BR112014016805A BR112014016805A BR112014016805A2 BR 112014016805 A2 BR112014016805 A2 BR 112014016805A2 BR 112014016805 A BR112014016805 A BR 112014016805A BR 112014016805 A BR112014016805 A BR 112014016805A BR 112014016805 A2 BR112014016805 A2 BR 112014016805A2
Authority
BR
Brazil
Prior art keywords
methods
therapeutically active
active compounds
administering
subject
Prior art date
Application number
BR112014016805A
Other languages
English (en)
Other versions
BR112014016805A8 (pt
BR112014016805B1 (pt
Inventor
Delabarre Byron
G Salituro Francesco
Cianchetta Giovanni
Popovici-Muller Janeta
O Saunders Jeffrey
Travins Jeremy
Zhang Li
Yan Shunqi
Guo Tao
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48744984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014016805(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of BR112014016805A2 publication Critical patent/BR112014016805A2/pt
Publication of BR112014016805A8 publication Critical patent/BR112014016805A8/pt
Publication of BR112014016805B1 publication Critical patent/BR112014016805B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

resumo compostos terapeuticamente ativos e seus métodos de uso proporcionam-se os compostos úteis para o tratamento de câncer e métodos para tratar o câncer compreendendo a administração a um sujeito que dele necessite um composto aqui descrito.
BR112014016805-9A 2012-01-06 2013-01-05 Compostos derivados de triazina, composição farmacêutica compreendendo os referidos compostos e seu uso para preparar um medicamento BR112014016805B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584214P 2012-01-06 2012-01-06
US61/584,214 2012-01-06
PCT/CN2013/000009 WO2013102431A1 (en) 2012-01-06 2013-01-05 Therapeutically active compounds and their methods of use

Publications (3)

Publication Number Publication Date
BR112014016805A2 true BR112014016805A2 (pt) 2017-06-13
BR112014016805A8 BR112014016805A8 (pt) 2017-07-04
BR112014016805B1 BR112014016805B1 (pt) 2019-07-30

Family

ID=48744984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014016805-9A BR112014016805B1 (pt) 2012-01-06 2013-01-05 Compostos derivados de triazina, composição farmacêutica compreendendo os referidos compostos e seu uso para preparar um medicamento

Country Status (39)

Country Link
US (7) US9732062B2 (pt)
EP (3) EP3406608B8 (pt)
JP (2) JP6411895B2 (pt)
KR (1) KR101893112B1 (pt)
CN (6) CN104114543B (pt)
AR (1) AR090411A1 (pt)
AU (2) AU2013207289B2 (pt)
BR (1) BR112014016805B1 (pt)
CA (1) CA2860623A1 (pt)
CL (1) CL2014001793A1 (pt)
CO (1) CO7030962A2 (pt)
CR (1) CR20140377A (pt)
CY (1) CY1120506T1 (pt)
DK (1) DK2800743T3 (pt)
EA (1) EA030187B1 (pt)
EC (1) ECSP14012726A (pt)
ES (2) ES2675760T3 (pt)
HK (1) HK1203942A1 (pt)
HR (1) HRP20180844T1 (pt)
HU (1) HUE038403T2 (pt)
IL (1) IL233503B (pt)
LT (1) LT2800743T (pt)
MX (1) MX358940B (pt)
MY (1) MY185206A (pt)
NI (1) NI201400073A (pt)
NO (1) NO2897546T3 (pt)
NZ (2) NZ627096A (pt)
PE (1) PE20142098A1 (pt)
PH (1) PH12014501561B1 (pt)
PL (1) PL2800743T3 (pt)
PT (1) PT2800743T (pt)
RS (1) RS57401B1 (pt)
SG (2) SG11201403878QA (pt)
SI (1) SI2800743T1 (pt)
TR (1) TR201809228T4 (pt)
TW (1) TWI653228B (pt)
UA (1) UA117451C2 (pt)
WO (1) WO2013102431A1 (pt)
ZA (1) ZA201405163B (pt)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
EP3708169A1 (en) 2009-06-29 2020-09-16 Agios Pharmaceuticals, Inc. 2,3-dihydrobenzo[b][1,4]dioxine-6-sulfonamide derivatives having an anticancer activity
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
HUE039269T2 (hu) 2011-05-03 2018-12-28 Agios Pharmaceuticals Inc Piruvát-kináz aktivátorok terápiában történõ alkalmazásra
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN104114543B (zh) 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
HUE049690T2 (hu) 2012-01-06 2020-10-28 Lundbeck La Jolla Research Center Inc Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
CN111087353B (zh) * 2013-07-11 2023-10-24 法国施维雅药厂 治疗活性化合物及其使用方法
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
AU2014287122B9 (en) 2013-07-11 2018-11-01 Les Laboratoires Servier N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
KR102316886B1 (ko) * 2013-08-02 2021-10-19 아지오스 파마슈티컬스 아이엔씨. 치료학적 활성 화합물 및 이의 사용방법
ES2886211T3 (es) * 2013-08-02 2021-12-16 Agios Pharmaceuticals Inc Compuestos terapéuticamente activos y sus métodos de uso
WO2015018060A1 (en) * 2013-08-09 2015-02-12 Agios Pharmaceuticals, Inc. Crystalline forms of therapeutically active compounds and use thereof
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
EA034366B1 (ru) * 2014-03-14 2020-01-31 Аджиос Фармасьютикалз, Инк Способ лечения распространённых солидных опухолей с помощью ингибитора idh1
CA2942072C (en) * 2014-03-14 2022-07-26 Agios Pharmaceuticals, Inc. Pharmaceutical compositions and use of (s)-1-(2-chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-( 4-cyanopyridin-2-yl)-n-( 5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide
CN106132946A (zh) * 2014-03-28 2016-11-16 巴斯夫欧洲公司 作为除草剂的二氨基三嗪衍生物
WO2015155129A1 (en) * 2014-04-07 2015-10-15 Basf Se Diaminotriazine compound
EP2930174A1 (en) * 2014-04-07 2015-10-14 Basf Se Diaminotriazine derivatives as herbicides
JP6820836B2 (ja) * 2014-09-19 2021-01-27 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
JP6648116B2 (ja) 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
MA40481A (fr) 2014-09-19 2017-07-26 Forma Therapeutics Inc Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante
WO2016053850A1 (en) * 2014-09-29 2016-04-07 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2975506A1 (en) * 2015-02-04 2016-08-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3271352B1 (en) 2015-03-18 2021-05-12 H. Lundbeck A/S Piperazine carbamates and methods of making and using same
EA038574B1 (ru) * 2015-04-21 2021-09-16 Форма Терапьютикс, Инк. Хинолиноновые производные пиридин-2(1h)-она и фармацевтические композиции на их основе
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US20180134683A1 (en) * 2015-05-07 2018-05-17 Teligene Ltd. Heterocylcic compounds as idh2 inhibitors
CA2984480A1 (en) 2015-05-11 2016-11-17 Abide Therapeutics, Inc. Methods of treating inflammation or neuropathic pain
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze
WO2017016513A1 (zh) * 2015-07-30 2017-02-02 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物及其使用方法
WO2017024134A1 (en) * 2015-08-05 2017-02-09 Agios Pharmaceuticals, Inc. Methods of preparing 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diols and 6-(aryl or heteroaryl)-1,3,5-triazine-2,4-diamines
EP3362065B1 (en) 2015-10-15 2024-04-03 Les Laboratoires Servier Combination therapy comprising ivosidenib, cytarabine and daunorubicin or idarubicin for treating acute myelogenous leukemia
SG11201803091PA (en) 2015-10-15 2018-05-30 Agios Pharmaceuticals Inc Combination therapy for treating malignancies
ES2862730T3 (es) 2015-10-15 2021-10-07 Celgene Corp Combinación de un inhibidor de isocitrato deshidrogenasa 2 mutante con azacitidina y su uso para el tratamiento de la leucemia mielógena aguda
EP3362057A1 (en) 2015-10-15 2018-08-22 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
AU2016340740B2 (en) * 2015-10-21 2018-07-19 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof
CA3007363A1 (en) 2015-12-04 2017-06-08 Agios Pharmaceuticals, Inc. Methods of treatment of malignancies
CN105399695B (zh) * 2015-12-11 2019-04-19 浙江大学 三嗪类化合物及其制备方法和用途
CN105503754B (zh) * 2015-12-11 2017-11-17 浙江大学 2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
CN105384702B (zh) * 2015-12-11 2018-04-10 浙江大学 三取代均三嗪类化合物及其制备方法
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
WO2017143283A1 (en) 2016-02-19 2017-08-24 Abide Therapeutics, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
KR20180114202A (ko) 2016-02-26 2018-10-17 아지오스 파마슈티컬스 아이엔씨. 혈액 악성종양 및 고형 종양의 치료를 위한 idh1 억제제
CN105753801B (zh) * 2016-03-25 2018-06-01 浙江工业大学 一种均三嗪类化合物的制备方法
CN105820133B (zh) * 2016-03-25 2018-06-05 浙江工业大学 多取代均三嗪类化合物及其制备方法和应用
CA3029343C (en) * 2016-07-21 2021-02-09 Nanjing Sanhome Pharmaceutical Co., Ltd. Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof
EP3493809B1 (en) * 2016-08-03 2023-08-23 Celgene Corporation Enasidenib for treatment of myelodysplastic syndrome
BR112019004356A2 (pt) 2016-09-07 2019-05-28 Agios Pharmaceuticals Inc composições de comprimido
JP7042804B2 (ja) 2016-09-19 2022-03-28 ルンドベック ラ ホーヤ リサーチ センター，インク． ピペラジンカルバメート、及びその製造と使用の方法
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CN113549056A (zh) 2017-01-22 2021-10-26 正大天晴药业集团股份有限公司 1,3,5-三嗪衍生物的盐及其晶体、它们的制备方法、药物组合物和用途
WO2018204787A1 (en) * 2017-05-05 2018-11-08 Memorial Sloan Kettering Cancer Center Methods of treatment of myeloproliferative neoplasm
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
CN109265444B (zh) * 2017-07-17 2022-03-11 南京圣和药业股份有限公司 取代的三嗪类idh抑制剂的光学异构体及其应用
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
CN110054617A (zh) * 2018-01-19 2019-07-26 南京圣和药业股份有限公司 三嗪类化合物、其制备方法及用途
CN110051673B (zh) * 2018-01-19 2022-03-11 南京圣和药业股份有限公司 一种包含三嗪类idh抑制剂的药物组合物及其用途
CN110054615B (zh) * 2018-01-19 2021-06-15 南京圣和药业股份有限公司 三嗪类idh抑制剂甲磺酸盐的晶型
CN110054616B (zh) * 2018-01-19 2021-11-23 南京圣和药业股份有限公司 三嗪类idh抑制剂的制备方法
CN112088001A (zh) 2018-05-15 2020-12-15 隆德贝克拉荷亚研究中心有限公司 Magl抑制剂
US11576906B2 (en) 2018-05-16 2023-02-14 Forma Therapeutics, Inc. Inhibiting mutant IDH-1
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
KR102328682B1 (ko) * 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092906A1 (en) 2018-11-02 2020-05-07 Celgene Corporation Co-crystals of 2-methyl-1 -[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl) pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions and methods of use thereof
US20210403452A1 (en) 2018-11-02 2021-12-30 Celgene Corporation Solid forms of 2-methyl-1-[(4-[6-(trifluoromethyl) pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl) amino]propan-2-ol
US20220017489A1 (en) 2018-11-02 2022-01-20 Celgene Corporation Solid dispersions for treatment of cancer
CN111662275B (zh) * 2019-03-08 2023-08-22 中国药科大学 苯磺酰胺类idh突变体抑制剂、其制备方法和用途
CN111662271B (zh) * 2019-03-08 2023-11-14 中国药科大学 具有idh突变体抑制活性的化合物及其制备方法与应用
WO2020239759A1 (en) 2019-05-27 2020-12-03 Sandoz Ag Amorphous enasidenib in a stabilized form
WO2021057975A1 (zh) * 2019-09-29 2021-04-01 贝达药业股份有限公司 突变型idh2抑制剂及其应用
EP4058028A1 (en) 2019-11-14 2022-09-21 Celgene Corporation Pediatric formulations for treatment of cancer
EP4139288A1 (en) 2020-04-21 2023-03-01 H. Lundbeck A/S Synthesis of a monoacylglycerol lipase inhibitor
CN111592524B (zh) * 2020-05-20 2023-11-17 温州市天聚万迅信息科技有限公司 恩西德尼的制备方法
WO2022074587A1 (en) * 2020-10-06 2022-04-14 Kures, Inc. Mu-opioid receptor agonists and uses therefor
EP4291198A1 (en) * 2021-02-12 2023-12-20 Les Laboratoires Servier Therapeutically active compounds and their methods of use
US11865079B2 (en) 2021-02-12 2024-01-09 Servier Pharmaceuticals Llc Therapeutically active compounds and their methods of use
CN113461660B (zh) * 2021-06-11 2022-08-02 浙江大学 2,4,6-三取代-1,3,5-均三嗪类化合物及制备和应用
WO2023174235A1 (zh) * 2022-03-15 2023-09-21 贝达药业股份有限公司 突变型idh1和idh2抑制剂及其应用
WO2023183520A1 (en) * 2022-03-24 2023-09-28 A2A Pharmaceuticals, Inc. Compositions and methods for treating cancer
CN114773320A (zh) * 2022-05-29 2022-07-22 重庆医科大学 1,3,5-三嗪化合物及其制备方法和用途
CN115536637A (zh) * 2022-10-24 2022-12-30 陕西中医药大学 一种均三嗪类衍生物及其合成方法与用途

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390529A (en) 1942-02-03 1945-12-11 Ernst A H Friedheim Hydrazino-1,3,5-triazino derivatives of substituted phenylarsenic compounds
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
US3867383A (en) 1971-03-29 1975-02-18 Ciba Geigy Corp Monoanthranilatoanilino-s-triazines
CH606334A5 (pt) 1974-06-21 1978-10-31 Ciba Geigy Ag
JPS58186682A (ja) 1982-04-27 1983-10-31 日本化薬株式会社 セルロ−ス又はセルロ−ス含有繊維材料の染色法
DE3512630A1 (de) 1985-04-06 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zum faerben oder bedrucken von cellulosefasern oder cellulosemischfasern
US5041443A (en) 1989-02-21 1991-08-20 Dainippon Pharmaceutical Co., Ltd. Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof
DE69010232T2 (de) 1989-03-03 1994-12-01 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanpyridin-Derivate, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten.
ATE130882T1 (de) 1990-07-12 1995-12-15 Ciba Geigy Ag Verfahren zur photochemischen und thermischen stabilisierung von polyamid-fasermaterialien.
JPH0499768A (ja) 1990-08-17 1992-03-31 Dainippon Pharmaceut Co Ltd ４―（４―フェニルピリジン―２―イル）ピペラジン―１―オキシド誘導体
AU665238B2 (en) 1992-02-28 1995-12-21 Zenyaku Kogyo Kabushiki Kaisha S-triazine derivative and remedy for estrogen-dependent diseases containing the same as active ingredient
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
FR2735127B1 (fr) 1995-06-09 1997-08-22 Pf Medicament Nouvelles piperazines heteroaromatiques utiles comme medicaments.
GB9602166D0 (en) 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5834485A (en) 1996-05-20 1998-11-10 Chiroscience Limited Quinoline sulfonamides and their therapeutic use
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
CA2271744A1 (en) 1996-11-14 1998-05-22 Isao Hashiba Cyanoethylmelamine derivatives and process for producing the same
US6399358B1 (en) 1997-03-31 2002-06-04 Thomas Jefferson University Human gene encoding human chondroitin 6-sulfotransferase
JPH11158073A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd アデノシンａ３拮抗剤
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
UY25842A1 (es) 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
WO2000075129A1 (en) 1999-06-07 2000-12-14 Shire Biochem Inc. Thiophene integrin inhibitors
ATE309207T1 (de) 1999-08-27 2005-11-15 Sugen Inc Phosphat-mimetika sowie behandlungsmethoden unter verwendung von phosphatase-inhibitoren
US20030104211A1 (en) 2000-07-03 2003-06-05 Hideki Masuda Gas-barrier film
MXPA03000458A (es) 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
WO2002102313A2 (en) 2001-06-19 2002-12-27 Bristol-Myers Squibb Company Pyrimidine inhibitors of phosphodiesterase (pde) 7
US7038046B2 (en) 2001-08-17 2006-05-02 Ciba Specialty Chemicals Corporation Triazine derivatives and their use as sunscreens
JP4753336B2 (ja) 2001-09-04 2011-08-24 日本化薬株式会社 新規アリル化合物及びその製法
WO2003037346A1 (en) * 2001-10-31 2003-05-08 Cell Therapeutics, Inc. 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer
US6878196B2 (en) 2002-01-15 2005-04-12 Fuji Photo Film Co., Ltd. Ink, ink jet recording method and azo compound
US20040067234A1 (en) 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
EP1546121B1 (en) 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
JP2004107220A (ja) 2002-09-13 2004-04-08 Mitsubishi Pharma Corp ＴＮＦ−α産生抑制剤
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
AU2003293333A1 (en) 2002-12-02 2004-06-23 Arqule, Inc. Method of treating cancers
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
EP1587519A4 (en) 2003-01-10 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2005035507A2 (en) 2003-10-10 2005-04-21 Bayer Pharmaceuticals Corporation 4-aminopyrimidine derivatives for treatment of hyperproliferative disorders
AU2003297904A1 (en) 2003-12-12 2005-07-14 University Of Maryland, Baltimore Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
US20050245508A1 (en) 2003-12-24 2005-11-03 Scios, Inc. Treatment of malignant gliomas with TGF-beta inhibitors
EP1796673A2 (en) 2004-09-23 2007-06-20 Reddy US Therapeutics, Inc. Novel pyrimidine compounds, process for their preparation and compositions containing them
US20100160324A1 (en) 2004-12-30 2010-06-24 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
US20080146570A1 (en) 2005-01-25 2008-06-19 Astrazeneca Ab Chemical Compounds
WO2006133420A2 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Treatment of patients with cancer therapy
AU2006283846B2 (en) 2005-08-26 2012-04-05 Merck Serono Sa Pyrazine derivatives and use as PI3K inhibitors
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
TW200815426A (en) 2006-06-28 2008-04-01 Astrazeneca Ab New pyridine analogues II 333
WO2008070661A1 (en) 2006-12-04 2008-06-12 Neurocrine Biosciences, Inc. Substituted pyrimidines as adenosine receptor antagonists
EP2120964A2 (en) 2006-12-15 2009-11-25 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
PT2152676E (pt) 2007-04-30 2013-06-25 Prometic Biosciences Inc Derivados de triazina, composições contendo tais derivados, e métodos de tratamento do cancro e de doenças autoimunes usando tais derivados
JP2010529193A (ja) 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
JP5506674B2 (ja) 2007-07-20 2014-05-28 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
WO2009027736A2 (en) * 2007-08-27 2009-03-05 Astrazeneca Ab 2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
KR20100064381A (ko) 2007-10-10 2010-06-14 다케다 야쿠힌 고교 가부시키가이샤 아미드 화합물
JP2011507910A (ja) 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター 真核生物の寿命を変更するための方法
JP5277685B2 (ja) 2008-03-26 2013-08-28 富士ゼロックス株式会社 電子写真感光体、画像形成装置、プロセスカートリッジ及び画像形成方法
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
CN101575408B (zh) 2008-05-09 2013-10-30 Mca技术有限公司 用作阻燃剂和光稳定剂的聚三嗪基化合物
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
TW201028381A (en) 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
ES2755139T3 (es) 2008-09-03 2020-04-21 Univ Johns Hopkins Alteraciones genéticas en la citrato deshidrogenasa y otros genes en gliomas malignos
US20100144722A1 (en) 2008-09-03 2010-06-10 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds as gata modulators
JP2010079130A (ja) 2008-09-29 2010-04-08 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP2010181540A (ja) 2009-02-04 2010-08-19 Fuji Xerox Co Ltd 電子写真感光体、プロセスカートリッジ、及び画像形成装置
JP5263304B2 (ja) 2009-02-06 2013-08-14 日本新薬株式会社 アミノピラジン誘導体及び医薬
CN108524505A (zh) 2009-03-13 2018-09-14 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CN102573485B (zh) 2009-06-08 2014-11-26 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
US8261872B2 (en) * 2009-06-08 2012-09-11 Clark Equipment Company Work machine having modular ignition switch keypad with latching output
US20120202818A1 (en) 2009-06-09 2012-08-09 California Capital Equity, Llc Ureidophenyl substituted triazine derivatives and their therapeutical applications
KR20120026611A (ko) 2009-06-09 2012-03-19 아브락시스 바이오사이언스, 엘엘씨 헷지호그 신호전달의 피리딜-트리아진 억제제
US20120101587A1 (en) 2009-07-10 2012-04-26 Milux Holding Sa Knee joint device and method
JP5473851B2 (ja) 2009-09-30 2014-04-16 富士フイルム株式会社 高分子フィルム、位相差フィルム、偏光板及び液晶表示装置
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
ES2594402T3 (es) 2009-10-21 2016-12-20 Agios Pharmaceuticals, Inc. Métodos y composiciones para trastornos relacionados con la proliferación celular
JP5967827B2 (ja) 2009-12-09 2016-08-10 アジオス ファーマシューティカルズ， インコーポレイテッド Ｉｄｈ変異体をもつことを特徴とする癌治療用の治療的活性化合物
WO2011123618A1 (en) 2010-04-01 2011-10-06 Agios Pharmaceuticals, Inc. Methods of identifying a candidate compound
US20130184222A1 (en) 2010-07-16 2013-07-18 Agios Pharmaceuticals, Inc Therapeutically active compositions and their methods of use
JP5907986B2 (ja) 2010-11-29 2016-04-26 ガリオン ファーマシューティカルズ インコーポレイテッド 呼吸制御障害または呼吸制御疾患の処置用の呼吸刺激薬としての化合物
TWI555737B (zh) 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102659765B (zh) 2011-12-31 2014-09-10 沈阳药科大学 嘧啶及三嗪类化合物的制备方法和应用
CN104114543B (zh) * 2012-01-06 2019-03-15 安吉奥斯医药品有限公司 治疗活性化合物及其使用方法
HUE049690T2 (hu) 2012-01-06 2020-10-28 Lundbeck La Jolla Research Center Inc Karbamátvegyületek és eljárások azok elõállítására és alkalmazására
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
EP2804850B1 (en) 2012-01-19 2018-08-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use

Also Published As

Publication number Publication date
US11505538B1 (en) 2022-11-22
TWI653228B (zh) 2019-03-11
CL2014001793A1 (es) 2014-11-07
SG11201403878QA (en) 2014-08-28
CN114933585A (zh) 2022-08-23
JP6409081B2 (ja) 2018-10-17
PT2800743T (pt) 2018-07-04
US9732062B2 (en) 2017-08-15
MX358940B (es) 2018-09-10
SG10201602862RA (en) 2016-05-30
AU2017265096A1 (en) 2017-12-14
CR20140377A (es) 2014-11-13
EP3406608B1 (en) 2021-09-15
US20160318903A1 (en) 2016-11-03
AR090411A1 (es) 2014-11-12
EP3406608A1 (en) 2018-11-28
NZ722582A (en) 2018-02-23
CN115536635A (zh) 2022-12-30
EP2800743B1 (en) 2018-04-04
AU2013207289B2 (en) 2017-09-21
ES2675760T3 (es) 2018-07-12
LT2800743T (lt) 2018-06-25
AU2013207289A2 (en) 2014-07-31
RS57401B1 (sr) 2018-09-28
JP2017075193A (ja) 2017-04-20
US20130190287A1 (en) 2013-07-25
PH12014501561A1 (en) 2014-10-08
UA117451C2 (uk) 2018-08-10
JP2015503571A (ja) 2015-02-02
BR112014016805A8 (pt) 2017-07-04
AU2013207289A1 (en) 2014-07-31
US9512107B2 (en) 2016-12-06
US20200079755A1 (en) 2020-03-12
KR20140113712A (ko) 2014-09-24
ECSP14012726A (es) 2016-01-29
TW201329054A (zh) 2013-07-16
CO7030962A2 (es) 2014-08-21
MX2014008350A (es) 2014-10-06
PH12014501561B1 (en) 2014-10-08
PL2800743T3 (pl) 2018-09-28
HK1203942A1 (en) 2015-11-06
EP3406608B8 (en) 2022-01-19
CN107417667A (zh) 2017-12-01
US20170044139A1 (en) 2017-02-16
NO2897546T3 (pt) 2018-01-13
DK2800743T3 (en) 2018-06-14
SI2800743T1 (en) 2018-08-31
PE20142098A1 (es) 2015-01-08
EA201491330A1 (ru) 2015-04-30
EP2800743A1 (en) 2014-11-12
HUE038403T2 (hu) 2018-10-29
BR112014016805B1 (pt) 2019-07-30
CN104114543B (zh) 2019-03-15
IL233503A0 (en) 2014-08-31
US20230250078A1 (en) 2023-08-10
KR101893112B1 (ko) 2018-08-30
ES2901430T3 (es) 2022-03-22
IL233503B (en) 2018-07-31
CY1120506T1 (el) 2019-07-10
AU2017265096B9 (en) 2019-09-05
HRP20180844T1 (hr) 2018-08-24
EA030187B1 (ru) 2018-07-31
CN107417667B (zh) 2020-04-10
US20220348554A1 (en) 2022-11-03
NI201400073A (es) 2014-12-22
WO2013102431A1 (en) 2013-07-11
JP6411895B2 (ja) 2018-10-24
AU2017265096B2 (en) 2019-08-08
CA2860623A1 (en) 2013-07-11
CN108912066A (zh) 2018-11-30
NZ627096A (en) 2017-02-24
ZA201405163B (en) 2018-05-30
US20170298045A1 (en) 2017-10-19
MY185206A (en) 2021-04-30
US9656999B2 (en) 2017-05-23
EP2800743A4 (en) 2015-08-26
TR201809228T4 (tr) 2018-07-23
CN115521264A (zh) 2022-12-27
CN108912066B (zh) 2022-06-24
EP3984997A1 (en) 2022-04-20
CN104114543A (zh) 2014-10-22
US10294215B2 (en) 2019-05-21

Similar Documents

Publication Publication Date Title
BR112014016805A8 (pt) compostos terapeuticamente ativos e seus métodos de uso
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
CR20140388A (es) Compuestos terapeuticamente activos y sus métodos de uso
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR112013007681A2 (pt) uso terapêutico de um agonista trl e terapia de combinação
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
BR112013001122A2 (pt) composições ativas terapêuticas e seu método de uso
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
WO2015003355A3 (en) Therapeutically active compounds and their methods of use
BR112015008447A2 (pt) métodos para tratar câncer
UY36207A (es) Inhibidores de la syk
PE20151995A1 (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
EA201391438A1 (ru) Производные сулиндака, применение и получение указанных производных
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
UA117809C2 (uk) Похідні бендамустину, споріднені сполуки та їхнє медичне застосування для лікування раку
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
CR20160054A (es) Compuestos terapeuticamente activos y sus métodos de uso
UY34069A (es) Semuloparina para la prevención de tromboembolismo venoso en pacientes con cáncer que están recibiendo quimioterapia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: AGIOS PHARMACEUTICALS, INC. (US)

B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: CIENCIA RELACIONADA COM O ART.229-C DA LPI (ANUENCIA PREVIA) (DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. )

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2013, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2013, OBSERVADAS AS CONDICOES LEGAIS